BGC > Product Search > Vericiguat | 1350653-20-1

Description :
Vericiguat is a potent guanylate cyclase stimulant under the development of Bayer HealthCare Pharmaceuticals. Direct stimulation of guanylate cyclase is emerging as a potential new approach for the treatment of renal disorders. In Aug 2016, Bayer in collaboration with Merck completed phase-I clinical trials in Coronary artery disease (In adults, In the elderly) in Germany. In Sep 2016, Phase-III clinical trials in Chronic heart failure in Germany, Hungary and Spain was on-going.

• Molecular Weight :426.39
• Purity :98%

Molecular Formula :
C19H16F2N8O2
Canonical SMILES :
COC(=O)NC1=C(N=C(N=C1N)C2=NN(C3=C2C=C(C=N3)F)CC4=CC=CC=C4F)N
InChI :
InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27)
InChIKey :
QZFHIXARHDBPBY-UHFFFAOYSA-N
Solubility :
Soluble in DMSO
Appearance :
Powder
Application :
Chronic heart failure; Coronary artery disease
Storage : -20°C Freezer
Synonyms :
BAY1021189; BAY 1021189; BAY-1021189; BAY10-21189; BAY-10-21189; BAY 10-21189; methyl (4,6-diamino-2-(5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)carbamate

More details are to be found here